Jian He

Dr. Jian He


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2022 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
GXGaozhe Xiao
Gaozhe Xiao
ZZZhikun Zhang
Zhikun Zhang
QCQiaoying Chen
Qiaoying Chen
TWTao Wu
Tao Wu
WSWei Shi
Wei Shi
JHJian He
Jian He

20 March 2024 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
KZKeyong Zhang
Keyong Zhang
YSYuanyuan Shi
Yuanyuan Shi
ZJZe Jin
Ze Jin
JHJian He
Jian He

29 February 2024 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
QZQiang Zhang
Qiang Zhang
XLXiyu Liu
Xiyu Liu
JHJian He
Jian He
Microneedles that can be inserted and attached to multiple organ sites are considered an innovative platform for delivering anti-tumor drugs, which can be used in various tumor treatment protocols.

20 November 2020 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
HBHong Bi
Hong Bi
JHJian He
Jian He
XHXu He
Xu He
JDJunyi Du
Junyi Du
MCMin Chen
Min Chen
ZJZhixian Jin
Zhixian Jin
Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) are highly prevalent potential risk factors for systemic disease. Previous studies have reported that COPD and OSA are major independent risk factors for cardio‑ or cerebrovascular diseases. The present study aimed to investigate the role of bone marrow mesenchymal stem cells (BMSCs) on vascular injury in a COPD‑OSA overlap syndrome (OS) rat model. Rats were randomly divided into three groups: Sham, OS model and BMSC. BMSC localization in major organs was detected via confocal laser fluorescence microscopy, and the aortic tissue pathological changes and related genes were measured using hematoxylin & eosin and Masson staining. Genes associated with vascular endothelial cell injury, including endothelin 1, vascular cell adhesion molecule 1 and endothelial nitric oxide synthase, were detected via reverse transcription‑quantitative PCR and western blotting. Apoptosis of vascular endothelial cells was detected using TUNEL and immunofluorescence assays. The endothelial cell marker CD31 in injured vessels was analyzed via immunohistochemistry. BMSCs migrated into the heart, liver, spleen, lung, kidney, brain and aorta in the OS model. The green fluorescence expression of BMSCs demonstrated the highest level in the lung, followed by the aorta. Aortic tissue had a more severe vascular injury and increased apoptosis in the model group compared with the BMSC group. Vascular endothelial cell apoptosis was decreased in the BMSC group compared with the model group. The findings suggested that BMSCs could repair vascular injury by inhibiting endothelial cell damage and apoptosis. These data provide a theoretical basis for the treatment of cardiovascular diseases caused by OS with BMSCs.

Verified
Journal Article
Open access
PDF file
QZQiang Zhang
Qiang Zhang
JNJintong Na
Jintong Na
XLXiyu Liu
Xiyu Liu
JHJian He
Jian He
Oncolytic Newcastle disease virus is a new type of cancer immunotherapy drug. This paper proposes a scheme for delivering oncolytic viruses using hydrogel microneedles. Gelatin methacryloyl (GelMA) was synthesized by chemical grafting, and GelMA microneedles encapsulating oncolytic Newcastle disease virus (NDV) were prepared by micro-molding and photocrosslinking. The release and expression of NDV were tested by immunofluorescence and hemagglutination experiments. The experiments proved that GelMA was successfully synthesized and had hydrogel characteristics. NDV was evenly dispersed in the allantoic fluid without agglomeration, showing a characteristic virus morphology. NDV particle size was 257.4 ± 1.4 nm, zeta potential was −13.8 ± 0.5 mV, virus titer TCID50 was 107.5/mL, and PFU was 2 × 107/mL, which had a selective killing effect on human liver cancer cells in a dose and time-dependent manner. The NDV@GelMA microneedles were arranged in an orderly cone array, with uniform height and complete needle shape. The distribution of virus-like particles was observed on the surface. GelMA microneedles could successfully penetrate 5% agarose gel and nude mouse skin. Optimal preparation conditions were freeze-drying. We successfully prepared GelMA hydrogel microneedles containing NDV, which could effectively encapsulate NDV but did not detect the release of NDV.

1 August 2023 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
XWXiaotian Wan
Xiaotian Wan
YZYiwen Zhang
Yiwen Zhang
YNYueli Nie
Yueli Nie
KZKeyong Zhang
Keyong Zhang
ZJZe Jin
Ze Jin
JHJian He
Jian He
Background and Objective: Transition metals are commonly used catalysts in bioorthogonal chemistry and have attracted extensive attention in biochemistry because of their efficient catalytic performance. In recent years, transition metal-mediated cycloaddition reactions, bond cleavage, and formation reactions are being actively explored for tumor treatment. However, the direct application of transition metals in complex biological environments has several problems, including poor solubility, toxicity, and easy inactivation. The combination of transition metals and nanomaterials can solve those problems by playing a bioorthogonal catalytic role in tumor treatment. In this review, we summarize some research on the application of transition metals modified by nanomaterials in tumor therapy and discuss the potential and challenges of transition metal-mediated bioorthogonal therapy in comprehensive tumor therapy. Methods: English literature on transition metal in cancer treatment was searched in PubMed and Web of Science. The main search terms were “cancer treatment”, “bioorthogonal reaction”, “transition metal”, “bioorthogonal catalysis”, etc. Key Content and Findings: This review summarizes research on several major transition metals that can be used for bioorthogonal catalysis with the assistance of nanomaterials in anti-tumor therapy. In addition, bioorthogonal catalysis is a new supplement to antitumor therapy. We have compiled the potential challenges of the clinical application of transition metal-based nanocatalysts, which lays the foundation for future research related to medicinal chemistry and targeted cancer therapy. Conclusions: Most of the transition metals still have a lot of room for exploration in cancer treatment research. We still need more research to confirm the feasibility of in vivo and clinical trials.